Advanced search
Publication Cover
Clinical Epidemiology Volume 14, 2022 - Issue
Submit an article Journal homepage
356
Views
4
CrossRef citations to date
0
Altmetric
Methodology

A Framework for Visualizing Study Designs and Data Observability in Electronic Health Record Data

Shirley V WangBrigham and Women’s Hospital, Harvard Medical School, Boston, MA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-7761-7090
ORCID Icon &
Sebastian SchneeweissBrigham and Women’s Hospital, Harvard Medical School, Boston, MA, USAORCID Iconhttps://orcid.org/0000-0003-2575-467X
ORCID Icon
Pages 601-608 | Published online: 29 Apr 2022

References

  • Eichler HG, Baird LG, Barker R, et al. From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients. Clin Pharmacol Ther. 2015;97(3):234–246. doi:10.1002/cpt.59
  • Ball R, Robb M, Anderson SA, Dal Pan G. The FDA’s sentinel initiative—a comprehensive approach to medical product surveillance. Clin Pharmacol Ther. 2015;99(3):265–268. doi:10.1002/cpt.320
  • Sun X, Tan J, Tang L, Guo JJ, Li X. Real world evidence: experience and lessons from China. BMJ. 2018;360:j5262. doi:10.1136/bmj.j5262
  • Makady A, Ham RT, de Boer A, et al. Policies for use of real-world data in Health Technology Assessment (HTA): a comparative study of six HTA agencies. Value Health. 2017;20(4):520–532. doi:10.1016/j.jval.2016.12.003
  • Schneeweiss S, Rassen JA, Brown JS, et al. Graphical depiction of longitudinal study designs in health care databases. Ann Intern Med. 2019;170(6):398–406. doi:10.7326/m18-3079
  • Happe LE, Brown JD, Gatwood J, Schneeweiss S, Wang S. Application of a graphical depiction of longitudinal study designs to managed care pharmacy research. J Manag Care Spec Pharm. 2020;26(3):268–274. doi:10.18553/jmcp.2020.26.3.268
  • Wang SV, Pinheiro S, Hua W, et al. STaRT-RWE: structured template for planning and reporting on the implementation of real world evidence studies. BMJ. 2021;372:m4856. doi:10.1136/bmj.m4856
  • Rassen JA, Bartels DB, Schneeweiss S, Patrick AR, Murk W. Measuring prevalence and incidence of chronic conditions in claims and electronic health record databases. Clin Epidemiol. 2019;11:1–15. doi:10.2147/CLEP.S181242
  • Lin KJ, Glynn RJ, Singer DE, Murphy SN, Lii J, Schneeweiss S. Out-of-system care and recording of patient characteristics critical for comparative effectiveness research. Epidemiology. 2018;29(3):356–363. doi:10.1097/EDE.0000000000000794
  • Lin KJ, Rosenthal GE, Murphy SN, et al. External validation of an algorithm to identify patients with high data-completeness in electronic health records for comparative effectiveness research. Clin Epidemiol. 2020;12:133–141. doi:10.2147/CLEP.S232540
  • Lin KJ, Singer DE, Glynn RJ, Murphy SN, Lii J, Schneeweiss S. Identifying patients with high data completeness to improve validity of comparative effectiveness research in electronic health records data. Clin Pharmacol Ther. 2018;103(5):899–905. doi:10.1002/cpt.861
  • Wang SV, Schneeweiss S. Assessing and interpreting real-world evidence studies: introductory points for new reviewers. Clin Pharmacol Ther. 2022;111(1):145–149. doi:10.1002/cpt.2398
  • Daniel G, Silcox C, Bryan J, et al. Characterizing RWD quality and relevancy for regulatory purposes; 2018. Available from: https://healthpolicy.duke.edu/sites/default/files/2020-03/characterizing_rwd.pdf. Accessed April 26, 2022.
  • U.S. Food & Drug Administration. Framework for FDA’s real world evidence program; 2018. Available from: https://www.fda.gov/downloads/ScienceResearch/SpecialTopics/RealWorldEvidence/UCM627769.pdf. Accessed January 31, 2019.
  • Schneeweiss S, Patorno E. Conducting real-world evidence studies on the clinical outcomes of diabetes treatments. Endocr Rev. 2021;42(5):658–690. doi:10.1210/endrev/bnab007
  • Lin KJ, Schneeweiss S. Considerations for the analysis of longitudinal electronic health records linked to claims data to study the effectiveness and safety of drugs. Clin Pharmacol Ther. 2016;100(2):147–159. doi:10.1002/cpt.359
  • Makadia R, Ryan PB. Transforming the premier perspective hospital database into the Observational Medical Outcomes Partnership (OMOP) common data model. Egems. 2014;2(1):1110. doi:10.13063/2327-9214.1110
  • Shoaibi A, Fortin SP, Weinstein R, Berlin JA, Ryan P. Comparative effectiveness of famotidine in hospitalized COVID-19 patients. Am J Gastroenterol. 2021;116(4):692–699. doi:10.14309/ajg.0000000000001153
  • Friends of Cancer Research. FOCR rwEndpoints use case: assessing frontline treatment regimens in real-world patients with Advanced Non-Small Cell Lung Cancer (aNSCLC); 2021. Available from: https://www.focr.org/sites/default/files/Treatment-Comparisons_SAP.pdf. Accessed March 31, 2021.
  • Stewart M, Norden AD, Dreyer N, et al. An exploratory analysis of real-world end points for assessing outcomes among immunotherapy-treated patients with advanced non–small-cell lung cancer. JCO Clin Cancer Inform. 2019;(3):1–15. doi:10.1200/cci.18.00155
  • Franklin JM, Pawar AS. Replication of the EMPAREG diabetes trial in healthcare claims. US National Library of Medicine, Available from: https://clinicaltrials.gov/ct2/show/NCT04215536?id=NCT04215536&draw=2&rank=1&load=cart. Accessed March 4, 2020.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.